Skip to main content

Table 5 Logistic regression analysis for minimum NIC of grade 0 (Uncoverage)

From: Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation

 

Univariate

Multivariate

 

OR

95% CI

p value

OR

95% CI

p value

Male

1.39

0.64–2.84

0.48

   

Age

(1 year increase)

1.00

0.98–1.03

0.98

   

BMI

(1 kg/m2 increase)

1.03

0.96–1.09

0.44

   

Hypertension

0.83

0.42–1.63

0.60

   

Dyslipidemia

1.39

0.73–2.65

0.35

   

DM

1.88

1.14–3.10

0.016

2.14

1.19–3.86

0.011

Aspirin*

0.33

0.02–5.32

0.44

   

Clopidogrel*

0.96

0.59–1.58

0.90

   

Prasugrel*

1.43

0.86–2.36

0.19

   

Ticlopidine*

0.22

0.03–1.73

0.20

   

Statin*

1.55

0.86–2.78

0.16

   

Follow-up duration

0.995

0.986–1.004

0.31

   

ACS

0.89

0.53–1.50

0.70

   

Pre-dilatation balloon maximum diameter

(1 mm increase)

1.11

0.75–1.66

0.60

   

Pre-dilatation balloon maximum inflation pressure

(1 atm increase)

1.04

0.97–1.12

0.26

   

Maximum stent diameter

(1 mm increase)

1.24

0.69–2.21

0.48

   

Minimum stent diameter

(1 mm increase)

0.90

0.51–1.60

0.72

   

Stent implantation pressure

(1 atm increase)

0.97

0.91–1.04

0.43

   

Post-dilatation balloon maximum diameter

(1 mm increase)

0.51

0.32–0.83

0.006

0.51

0.31–0.86

0.011

Post-dilatation balloon maximum inflation pressure

(1 mm increase)

0.93

0.87–0.990

0.048

0.93

0.86–1.001

0.052

At the time of PCI

      

Total cholesterol

(1 mg/dL increase)

0.995

0.989–1.002

0.18

   

Triglyceride

(1 mg/dL increase)

1.000

0.998–1.003

0.68

   

HDL-cholesterol

(1 mg/dL increase)

0.995

0.976–1.014

0.60

   

LDL-cholesterol

(1 mg/dL increase)

0.994

0/987-1.002

0.15

   

At the time of CAS evaluation

      

Total cholesterol

(1 mg/dL increase)

0.997

0.990–1.005

0.47

   

Triglyceride

(1 mg/dL increase)

1.001

0.999–1.003

0.50

   

HDL-cholesterol

(1 mg/dL increase)

0.992

0.975–1.010

0.38

   

LDL-cholesterol

(1 mg/dL increase)

0.997

0.987–1.007

0.56

   
  1. * Medication at the time of coronary angioscopic evaluation. ACS  acute coronary syndrome, BMI body mass index, CAS  coronary angioscopy, DM   diabetes mellitus, HDL high-density lipoprotein, LDL low-density lipoprotein, PCI  percutaneous coronary intervention